Red light therapy for nearsighted kids: what happens when it stops?

NCT ID NCT07748546

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial studies children aged 8 to 16 who have used repeated low-level red light (RLRL) therapy for one year to control nearsightedness (myopia). Participants are randomly assigned to either continue the therapy, stop it completely, or gradually reduce it. The goal is to see how each approach affects eye growth and vision, specifically whether stopping causes a rebound effect that speeds up myopia progression. The findings could help doctors design better long-term treatment plans for children with myopia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Repeated low-level red light (RLRL) therapy, a device-based treatment using red light to slow myopia progression
What this could lead to
If successful, this trial could reveal the best way to stop or taper red light therapy without losing its benefits, helping children maintain better vision long-term.
What could go wrong
The trial is relatively small and focuses on a specific age group, so results may not apply to all children. There is also a risk that rebound effects occur regardless of how treatment is stopped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.